Designing Longevity
Skip to main content

Evidence guide

Energy peptides: human evidence, product status and safety

Review what MOTS-c and elamipretide research actually tested, where Forzinity approval applies, and why the exact product matters.

Read more
  • A cell marker, a mouse performance result and a person feeling less fatigued are different outcomes. Check what was measured. See details
  • The reviewed Forzinity evidence concerns a specific Barth syndrome use, not ordinary fatigue. See details

By Designing Longevity Editorial · Sources reviewed October 31, 2026 · How we work

Which outcome was measured?

A change in a cell marker, a mouse running result and a person feeling less fatigued are three different outcomes. Check which one a peptide claim actually measured.

Sources: [1] [2] [3]

What is a mitochondrial stack?

In online forums, a “ stack” can mean combining MOTS-c, SS-31 and NAD+. We found no published human trial of this combination showing it improves everyday fatigue or endurance, or establishing its safety. Human MOTS-c research measured the body’s own peptide around exercise. Researchers tested administered MOTS-c in mice. A small human study of SS-31 (elamipretide) found a short-term change in muscle ATP production without a clear improvement in muscle fatigue resistance. FDA of Forzinity covers muscle strength in adults and children with Barth syndrome weighing at least 30 kilograms. A small NAD+ infusion study measured blood and urine markers and did not test how people felt or functioned. Feeling less tired or walking farther requires direct testing.

Sources: [1] [4] [5] [6] [7]

MOTS-c in people and mice

In the cited MOTS-c exercise study, investigators measured the body's own MOTS-c response in ten young men. They administered MOTS-c to mice and measured physical performance. It was not a trial of administered MOTS-c for fatigue or endurance in people. In a 2026 advisory briefing, FDA said its review did not identify clinical studies or human exposure data for administered MOTS-c. That bounded review is background for an advisory meeting, not a final determination or proof that no study exists anywhere.

Sources: [1] [5]

What Forzinity is approved to do

Forzinity is a specific prescription elamipretide injection with accelerated FDA approval to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kilograms. That approval does not extend to ordinary fatigue or healthy-adult energy.

Sources: [8] [4]

Where to ask about Forzinity coverage

If your specialist has prescribed Forzinity for Barth syndrome, the manufacturer describes Mito Assist as a no-cost support program in the United States. The program can help you understand coverage and access. AnovoRx lists a prescriber enrollment route. Ask your plan which pharmacy it covers and whether authorization is needed, then ask the pharmacy for a separate quote for the medicine. Assistance and coverage depend on eligibility, and applying does not guarantee either.

Sources: [9] [10]

What clinical trials measured

The small randomized Barth syndrome trial did not meet its original walking-distance or fatigue endpoints; the FDA approval relied on knee extensor strength as an intermediate endpoint and requires confirmation of clinical benefit. In a separate primary myopathy trial, elamipretide did not improve walking distance or fatigue over 24 weeks versus placebo.

Sources: [8] [11] [2] [3]

Product identity matters

An FDA-approved finished medicine and a research-labeled vial do not share approval or quality review merely because both use the name elamipretide or SS-31. drugs are also not FDA-approved, though lawful compounding can meet some individual medical needs.

Sources: [4] [12]

Safety and route limits

Forzinity's label includes injection-site reactions and warnings. Do not use the label to predict the safety of other products or routes.

Sources: [4] [11]

Where to go next

Sources and dates

The source date describes the source itself. The review date records when we checked it for this page. These checks do not mean continuous monitoring or establish current product terms.

  1. [1]Reynolds et al., Nature Communications 2021, DOI 10.1038/s41467-020-20790-0, PMID 33473109 · Source date: 2021-01-20; appraised 2026-10-31 · Reviewed
  2. [2]Primary Barth syndrome elamipretide trial, PMID 33077895 · Source date: appraised 2026-10-31; original publication date not asserted here · Reviewed
  3. [3]MMPOWER-3 randomized clinical trial, PMID 37268435 · Source date: 2023 publication; appraised 2026-10-31 · Reviewed
  4. [4]US Food and Drug Administration prescribing information · Source date: 2025 label; accessed 2026-10-31 · Reviewed
  5. [5]US Food and Drug Administration, July 2026 PCAC evaluation of MOTS-c bulk substances · Source date: briefing dated 2026-05-11 for July 2026 advisory meeting · Reviewed
  6. [6]Roshanravan et al., PLOS ONE, PMID 34264994 · Source date: 2021-07-15 · Reviewed
  7. [7]Grant et al., Frontiers in Aging Neuroscience, PMID 31572171 · Source date: 2019-09-12 · Reviewed
  8. [8]US Food and Drug Administration · Source date: 2025-09-19; accessed 2026-10-31 · Reviewed
  9. [9]Stealth BioTherapeutics: Forzinity support and resources · Source date: Date not stated in the source · Reviewed
  10. [10]AnovoRx: Forzinity prescriber intake · Source date: Date not stated in the source · Reviewed
  11. [11]US Food and Drug Administration trial snapshot · Source date: approval 2025-09-19; accessed 2026-10-31 · Reviewed
  12. [12]US Food and Drug Administration · Source date: accessed 2026-10-31 · Reviewed

Designing Longevity is a founder-led editorial publication. Our content is not medically reviewed.

See a problem or outdated information? Tell us.